Federal Register / Vol. 76, No. 11 / Tuesday, January 18, 2011 / Rules and Regulations 2805 

Accordingly, part 748 of the EAR (15 

CFR Parts 730–774) is amended as 

follows: 

PART 748—[AMENDED] 

■ 1. The authority citation for 15 CFR 

Part 748 continues to read as follows: 

Authority: 50 U.S.C. app. 2401 et seq.; 50 

U.S.C. 1701 et seq.; E.O. 13026, 61 FR 58767, 

3 CFR, 1996 Comp., p. 228; E.O. 13222, 66 

FR 44025, 3 CFR, 2001 Comp., p. 783; Notice 

of August 12, 2010, 75 FR 50681 (August 16, 

2010). 

■ 2. Supplement No. 7 to Part 748 is 

amended: 

■ a. By adding one entry, ‘‘CSMC 

Technologies Corporation’’, for ‘‘China 

(People’s Republic of)’’ in alphabetical 

order; and 

■ b. By revising the entry for ‘‘Advanced 

Micro Devices (Shanghai) Co., Ltd.’’ for 

‘‘China (People’s Republic of)’’ to read as 

follows: 

SUPPLEMENT NO. 7 TO PART 748— 

AUTHORIZATION VALIDATED ENDUSER (VEU); LIST OF VALIDATED 

END-USERS, RESPECTIVE ITEMS 

ELIGIBLE FOR EXPORT, REEXPORT 

AND TRANSFER, AND ELIGIBLE 

DESTINATIONS 

Country Validated end-user Eligible items (by ECCN) Eligible destination 

China (People’s 

Republic of).

Advanced Micro Devices China, Inc. ....................... 3D002, 3D003, 3E001 (limited to 

‘‘technology’’ for items classified 

under 3C002 and 3C004 and 

‘‘technology’’ for use during the 

International Technology Roadmap for Semiconductors (ITRS) 

process for items classified 

under ECCNs 3B001 and 

3B002), 3E002 (limited to 

‘‘technology’’ for use during the 

ITRS process for items classified under ECCNs 3B001 and 

3B002), 3E003.e (limited to the 

‘‘development’’ and ‘‘production’’ 

of integrated circuits for commercial applications), 4D001, 

4D002, 4D003 and 4E001 (limited to the ‘‘development’’ of 

products under ECCN 4A003).

AMD Technologies (China) Co., 

Ltd., No. 88, Su Tong Road, 

Suzhou, China 215021. 

Advanced Micro Devices (Shanghai) Co., Ltd., Buildings 46, 47, 

48 & 49, River Front Harbor, 

Zhangjiang Hi-Tech Park, 1387 

Zhangdong Rd., Pudong, 

Shanghai, 201203. 

AMD Technology Development 

(Beijing) Co., Ltd., 18F, North 

Building, Raycom Infotech, Park 

Tower C, No. 2 Science Institute South Rd., Zhong Guan 

Cun, Haidian District, Beijing, 

China 100190. 

*******

CSMC Technologies Corporation ............................. 1C350.c.3, 1C350.c.11, 2B230.a, 

2B230.b, 2B350.f, 2B350.g, 

2B350.h, 3B001.c.1.a, 

3B001.c.2.a, 3B001.e, 3C002.a, 

3C004.

CSMC Technologies Fab 1 Co., 

Ltd., 14 Liangxi Road, Wuxi, 

Jiangsu 214061, China. 

CSMC, Technologies Fab 2 Co., 

Ltd., Block 86, 87, Wuxi National Hi-New Tech Industrial 

Development Zone, Wuxi, 

Jiangsu 214061, China. 

Wuxi CR Semiconductor Wafers 

and Chips Co., Ltd., 14 Liangxi 

Road, Wuxi, Jiangsu 214061, 

China. 

*******

Dated: January 11, 2011. 

Kevin J. Wolf, 

Assistant Secretary for Export 

Administration. 

[FR Doc. 2011–920 Filed 1–14–11; 8:45 am] 

BILLING CODE 3510–33–P 

SECURITIES AND EXCHANGE 

COMMISSION 

17 CFR Part 200 

[Release No. 34–63699] 

Delegation of Authority to the Chief 

Accountant 

AGENCY: Securities and Exchange 

Commission. 

ACTION: Final rule. 

SUMMARY: The Securities and Exchange 

Commission is amending its rules to 

delegate authority to the Chief 

Accountant with respect to proposed 

rule changes of the Public Company 

Accounting Oversight Board pursuant to 

Section 107 of the Sarbanes-Oxley Act 

of 2002 and Section 19(b) of the 

Securities Exchange Act of 1934, as 

follows: To publish notices of proposed 

rule changes filed by the PCAOB; to 

approve or disapprove a proposed rule 

change; and to temporarily suspend a 

proposed rule of the PCAOB. In 

addition, the Commission is amending 

its rules to delegate authority to the 

Chief Accountant to determine the 

appropriateness of extending the time 

periods specified in Section 19(b) and 

publish the reasons for such 

determination as well as to effect any 

such extension and to institute 

proceedings to determine whether to 

disapprove a proposal and to provide to 

the PCAOB notice of the grounds for 

disapproval under consideration, and to 

find good cause to approve a proposal 

on an accelerated basis and to publish 

the reasons for such determination. This 

delegation is intended to conserve 

Commission resources and to maintain 

the effectiveness and efficiency of the 

Commission’s PCAOB proposed rule 

filing process. 

DATES: Effective Date: January 18, 2011. 

FOR FURTHER INFORMATION CONTACT: 

Jeffrey S. Cohan, Senior Special 

Counsel, or John F. Offenbacher, Senior 

Associate Chief Accountant, at (202) 

551–5300, Office of the Chief 

Accountant, Securities and Exchange 

WReier-Aviles on DSKDVH8Z91PROD with RULES

2806 Federal Register / Vol. 76, No. 11 / Tuesday, January 18, 2011 / Rules and Regulations 

1See Section 107 of the Sarbanes-Oxley Act, 15 

U.S.C. 7217. 

2See 15 U.S.C. 78s(b)(2). 

3 Dodd-Frank Wall Street Reform and Consumer 

Protection Act, Pub. L. 111–203, 124 Stat. 1376 

(2010). 

4 15 U.S.C. 78s(b)(2). Section 107(b) of the 

Sarbanes Oxley Act, 15 U.S.C. 7217(b), and Section 

19(b)(2)(C) of the Exchange Act, 15 U.S.C. 

78s(b)(2)(C), provide the standards for Commission 

approval and disapproval of a proposed rule. 

Specifically, Section 107(b)(3) provides that the 

Commission ‘‘shall approve a proposed rule if it 

finds that the rule is consistent with the 

requirements of this Act and the securities laws, or 

is necessary and appropriate in the public interest 

or for the protection of investors.’’ Additionally, the 

Commission may not approve a proposed rule 

change earlier than 30 days after the date of 

publication unless the Commission finds good 

cause for so doing and publishes the reasons for the 

finding. 

5The amendments also specify that the Office of 

the Chief Accountant is to notify the Commission 

no less than five (5) business days before the Chief 

Accountant intends to exercise his or her authority 

to approve or disapprove a particular proposed rule 

change. 

6 15 U.S.C. 78s(b)(2)(A). 

7 15 U.S.C. 78s(b)(2)(A). 

8 15 U.S.C. 78s(b)(2)(B). 

9 15 U.S.C. 78s(b)(3)(C). 

Commission, 100 F Street, NE., 

Washington, DC 20549–7561. 

SUPPLEMENTARY INFORMATION: 

I. Discussion of Rule Amendments 

Pursuant to the Sarbanes-Oxley Act of 

2002 (‘‘Sarbanes-Oxley Act’’),1 proposed 

rules of the Public Company Accounting 

Oversight Board (‘‘PCAOB’’) are 

governed by certain provisions of 

Section 19 of the Securities Exchange 

Act of 1934 (‘‘Exchange Act’’).2 The 

Dodd-Frank Wall Street Reform and 

Consumer Protection Act 3 amended 

Section 19 of the Exchange Act so that 

there are new deadlines by which the 

Securities and Exchange Commission 

(‘‘Commission’’) must publish and act 

upon proposed rule changes submitted 

by the PCAOB. In recognition of the 

amendments to Section 19, the 

Commission is amending its rules 

governing delegations of authority to the 

Chief Accountant. The amendments to 

Rule 30–11 (17 CFR 200.30–11) 

authorize the Chief Accountant: (1) To 

publish notice of a PCAOB proposed 

rule change pursuant to Section 

19(b)(1); (2) pursuant to Section 19(b)(2) 

of the Exchange Act, to approve or 

disapprove 4 a PCAOB proposed rule 

change; 5 (3) pursuant to Section 

19(b)(2)(A) of the Exchange Act,6 to 

extend for a period not exceeding 90 

days from the date of publication of 

notice of the filing of a proposed rule 

change the period during which the 

Commission must by order approve or 

disapprove the proposed rule change; 

(4) pursuant to Section 19(b)(2)(A) of the 

Exchange Act,7 to determine the 

appropriateness of extending the period 

during which the Commission must by 

order approve or disapprove a proposed 

rule change or institute proceedings to 

determine whether to disapprove the 

proposal and publish the reasons for 

such determination; (5) pursuant to 

Section 19(b)(2)(B) of the Exchange 

Act,8 to extend for a period not 

exceeding 240 days from the date of 

publication of notice of the filing of a 

proposed rule change the period during 

which the Commission must conclude 

proceedings to determine whether to 

disapprove the proposal and to 

determine whether such longer period is 

appropriate and publish the reasons for 

such determination; (6) to temporarily 

suspend the PCAOB’s proposed rule 

change pursuant to Section 19(b)(3)(C) 

of the Exchange Act; 9 (7) pursuant to 

Section 19(b)(2) of the Exchange Act 

and 19(b)(3) of the Exchange Act, to 

institute proceedings to determine 

whether a proposed rule of the PCAOB 

should be disapproved and to provide to 

the PCAOB notice of the grounds for 

disapproval under consideration; and 

(8) to find good cause to approve a 

proposal on an accelerated basis and to 

publish the reasons for such 

determination. 

This delegation is intended to 

conserve Commission resources and 

maintain the effectiveness and 

efficiency of the Commission’s process 

for handling proposed rule changes 

submitted by the PCAOB. The 

Commission anticipates that the 

delegation of authority will help 

facilitate timely compliance with the 

amendments to Section 19 of the 

Exchange Act and the new statutory 

deadlines prescribed therein. 

Nevertheless, the Chief Accountant may 

submit matters to the Commission for its 

consideration, as he or she deems 

appropriate. 

The Commission finds, in accordance 

with the Administrative Procedure Act 

(5 U.S.C. 553(b)(3)(A)), that these 

amendments relate solely to agency 

organization, procedures, or practices, 

and do not relate to a substantive rule. 

Accordingly, notice, opportunity for 

public comment, and publication of the 

amendments prior to their effective date 

are unnecessary and these changes are 

effective on January 18, 2011. 

List of Subjects in 17 CFR Part 200 

Administrative practice and 

procedure, Authority delegations 

(Government agencies). 

Text of Amendment 

For the reasons set out in the 

preamble, Title 17, Chapter II of the 

Code of Federal Regulations is amended 

as follows: 

PART 200—ORGANIZATION; 

CONDUCT AND ETHICS; AND 

INFORMATION AND REQUESTS 

■ 1. The authority citation for Part 200, 

Subpart A, continues to read in part as 

follows: 

Authority: 15 U.S.C. 77o, 77s, 77sss, 77d, 

78d–1, 78d–2, 78w, 78ll(d), 78mm, 80a–37, 

80b–11, and 7202 et seq., unless otherwise 

noted. 

* * * * * 

■ 2. Section 200.30–11 is amended as 

follows: 

■ a. Redesignating paragraph (b) as 

paragraph (c). 

■ b. Adding new paragraph (b). 

The addition reads as follows: 

§ 200.30–11 Delegation of authority to the 

Chief Accountant. 

* * * * * 

(b)(1) Pursuant to section 107 of the 

Sarbanes-Oxley Act of 2002, 15 U.S.C. 

7217, and section 19(b) of the Act, 15 

U.S.C. 78s(b), and applicable rules of 

the Commission, to publish notices of 

proposed rule changes filed by the 

Public Company Accounting Oversight 

Board. 

(2) Pursuant to section 107 of the 

Sarbanes-Oxley Act of 2002, 15 U.S.C. 

7217, and section 19(b) of the Act, 15 

U.S.C. 78s(b), and applicable rules of 

the Commission, to approve or 

disapprove a proposed rule change, and 

to find good cause to approve a 

proposed rule change earlier than 30 

days after the date of publication of 

such proposed rule change and to 

publish the reasons for such finding. 

The Office of the Chief Accountant shall 

notify the Commission no less than five 

(5) business days before the Chief 

Accountant intends to exercise his or 

her authority to approve or disapprove 

a particular proposed rule change. 

(3) Pursuant to section 107 of the 

Sarbanes-Oxley Act of 2002, 15 U.S.C. 

7217, and section 19(b)(2)(A) of the Act, 

15 U.S.C. 78s(b)(2)(A), to extend for a 

period not exceeding 90 days from the 

date of publication of notice of the filing 

of a proposed rule change pursuant to 

section 19(b)(1) of the Act, 15 U.S.C. 

78s(b)(1), the period during which the 

Commission must by order approve or 

disapprove the proposed rule change or 

institute proceedings to determine 

whether the proposed rule change 

should be disapproved and to determine 

whether such longer period is 

appropriate and publish the reasons for 

such determination. 

(4) Pursuant to section 107 of the 

Sarbanes-Oxley Act of 2002, 15 U.S.C. 

WReier-Aviles on DSKDVH8Z91PROD with RULES

Federal Register / Vol. 76, No. 11 / Tuesday, January 18, 2011 / Rules and Regulations 2807 

7217, section 19(b)(2) of the Act, 15 

U.S.C. 78s(b)(2), and section 19(b)(3) of 

the Act, 15 U.S.C. 78s(b)(3), to institute 

proceedings to determine whether a 

proposed rule change of the Public 

Company Accounting Oversight Board 

should be disapproved and to provide to 

the Public Company Accounting 

Oversight Board notice of the grounds 

for disapproval under consideration. In 

addition, pursuant to section 107 of the 

Sarbanes-Oxley Act of 2002, 15 U.S.C. 

7217, and section 19(b)(2)(B) of the Act, 

15 U.S.C. 78s(b)(2)(B), to extend for a 

period not exceeding 240 days from the 

date of publication of notice of the filing 

of a proposed rule change pursuant to 

section 19(b)(1) of the Act, 15 U.S.C. 

78s(b)(1), the period during which the 

Commission must issue an order 

approving or disapproving the proposed 

rule change and to determine whether 

such longer period is appropriate and 

publish the reasons for such 

determination. 

(5) Pursuant to section 107 of the 

Sarbanes-Oxley Act of 2002, 15 U.S.C. 

7217, and section 19(b)(3)(C) of the Act, 

15 U.S.C. 78s(b)(3)(C), to temporarily 

suspend a rule of the Public Company 

Accounting Oversight Board. 

* * * * * 

Dated: January 11, 2011. 

By the Commission. 

Elizabeth M. Murphy, 

Secretary. 

[FR Doc. 2011–835 Filed 1–14–11; 8:45 am] 

BILLING CODE 8011–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

21 CFR Part 510 

[Docket No. FDA–2010–N–0002] 

New Animal Drugs; Change of Sponsor 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Final rule. 

SUMMARY: The Food and Drug 

Administration (FDA) is amending the 

animal drug regulations to reflect a 

change of sponsor for hemoglobin 

glutamer-200 from Biopure Corp. to 

OPK Biotech, LLC. 

DATES: This rule is effective January 18, 

2011. 

FOR FURTHER INFORMATION CONTACT: 

Steven D. Vaughn, Center for Veterinary 

Medicine (HFV–100), Food and Drug 

Administration, 7520 Standish Pl., 

Rockville, MD 20855, 240–276–8300, 

e-mail: steven.vaughn@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Biopure 

Corp., 11 Hurley St., Cambridge, MA 

02141 has informed FDA that it has 

transferred ownership of, and all rights 

and interest in, NADA 141–067 for 

OXYGLOBIN (hemoglobin glutamer200) to OPK Biotech, LLC, 11 and 39 

Hurley St., Cambridge, MA 02141. 

There is no change in drug labeler code. 

Following this change of sponsorship, 

Biopure Corp. is no longer the sponsor 

of an approved application. In addition, 

OPK Biotech, LLC, is not currently 

listed in the animal drug regulations as 

a sponsor of an approved application. 

Accordingly, § 510.600 is being 

amended to reflect these changes. 

This rule does not meet the definition 

of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because 

it is a rule of ‘‘particular applicability.’’ 

Therefore, it is not subject to the 

congressional review requirements in 5 

U.S.C. 801–808. 

List of Subjects in 21 CFR Part 510 

Administrative practice and 

procedure, Animal drugs, Labeling, 

Reporting and recordkeeping 

requirements. 

Therefore, under the Federal Food, 

Drug, and Cosmetic Act and under 

authority delegated to the Commissioner 

of Food and Drugs and redelegated to 

the Center for Veterinary Medicine, 21 

CFR part 510 is amended as follows: 

PART 510—NEW ANIMAL DRUGS 

■ 1. The authority citation for 21 CFR 

part 510 continues to read as follows: 

Authority: 21 U.S.C. 321, 331, 351, 352, 

353, 360b, 371, 379e. 

■ 2. In § 510.600, in the table in 

paragraph (c)(1), remove the entry for 

‘‘Biopure Corp.’’; and alphabetically add 

a new entry for ‘‘OPK Biotech, LLC’’; and 

in the table in paragraph (c)(2), revise 

the entry for ‘‘063075’’ to read as 

follows: 

§ 510.600 Names, addresses, and drug 

labeler codes of sponsors of approved 

applications. 

* * * * * 

(c) * * * 

(1) * * * 

Firm name and address 

Drug 

labeler 

code 

* * * * * 

OPK Biotech, LLC, 11 and 39 

Hurley St., Cambridge, MA 

02141 ........................................ 063075 

* * * * * 

(2) * * * 

Drug labeler 

code 

Firm name and address 

* * * * * 

063075 OPK Biotech, LLC, 11 and 39 

Hurley St., Cambridge, MA 

02141 

* * * * * 

Dated: January 11, 2011. 

Steven D. Vaughn, 

Director, Office of New Animal Drug 

Evaluation, Center for Veterinary Medicine. 

[FR Doc. 2011–904 Filed 1–14–11; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

21 CFR Parts 510 and 522 

[Docket No. FDA–2010–N–0002] 

New Animal Drugs; Change of 

Sponsor; Follicle Stimulating Hormone 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Final rule. 

SUMMARY: The Food and Drug 

Administration (FDA) is amending the 

animal drug regulations to reflect a 

change of sponsor for a new animal drug 

application (NADA) for follicle 

stimulating hormone from Ausa 

International, Inc., to Therio, Inc. 

DATES: This rule is effective January 18, 

2011. 

FOR FURTHER INFORMATION CONTACT: 

Steven D. Vaughn, Center for Veterinary 

Medicine (HFV–100), Food and Drug 

Administration, 7520 Standish Pl., 

Rockville, MD 20855, 240–276–8300, 

e-mail: steven.vaughn@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Ausa 

International, Inc., Rt. 8, P.O. Box 324– 

12, Tyler, TX 75703 has informed FDA 

that it has transferred ownership of, and 

all rights and interest in, NADA 141– 

014 for SUPER–OV (follicle stimulating 

hormone) to Therio, Inc., 8801 

Anderson Ave., Manhattan, KS 66503. 

Accordingly, the Agency is amending 

the regulations in 21 CFR 522.1002 to 

reflect the transfer of ownership. 

Following this change of sponsorship, 

Ausa International, Inc., is no longer the 

sponsor of an approved application. 

Accordingly, § 510.600 (21 CFR 

510.600) is being amended to remove 

the entries for this firm. 

WReier-Aviles on DSKDVH8Z91PROD with RULES